NCT01194804View on ClinicalTrials.gov

E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

March 31, 2011

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

Eculizumab

Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.

Sponsors
All Listed Sponsors
collaborator

CMIC Co, Ltd. Japan

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY